ribosomal protein L12 pseudogene 13Genealiases: []
Q-omics provides the consensus-scored RPL12P13 profile across patient tissues and cancer cell-line models. RPL12P13 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL12P13 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, RPL12P13 RNA expression shows 6,838 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where RPL12P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL12P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL12P13 survival associations across molecular data types. RPL12P13 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL12P13 RNA expression–survival associations across cancer types. High RPL12P13 expression shows unfavorable associations in ACC, LIHC, READ and THCA, but favorable associations in LUSC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL12P13 RNA expression.
This table summarizes RPL12P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL12P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL12P13 shows higher tumor expression in COAD, KIRC, LUSC, LUAD, KIRP and READ. The COAD box plot shows higher RPL12P13 RNA expression in tumor versus normal tissue (log2 FC = +0.397, t-test p < 0.001).
This table shows molecular features associated with RPL12P13 in patient tissues and cancer cell lines. In patient samples, RPL12P13 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
